Mesoblast LTD cash flow statement

In fiscal 2026, Mesoblast LTD's operations generated −$43.8m of cash; it spent $833,000 on capital projects, leaving free cash flow of −$44.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Mesoblast LTD: cash flow statement, annual
Fiscal year	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025	2026Jun 2026
Cash from operations	−88	−95	−75	−58	−50	−101	−66	−63	−48	−50	−44
Depreciation and amortisation	2	3	3	2	4	4	4	4	5	2	2
Stock-based pay	3	5	6	4	8	13	6	4	6	22	15
Capital spending	—	—	—	—	—	—	—	0	0	1	1
Free cash flow	—	—	—	—	—	—	—	−64	−49	−51	−45
Free cash flow after stock pay	—	—	—	—	—	—	—	−67	−55	−73	−60

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: MESO vs RCUS MESO vs SPRY AGEN vs MESO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mesoblast LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mesoblast LTD.